Tscan Therapeutics, Inc.(TCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TCRX Tscan Therapeutics, Inc.

交易中 03-13 09:58:48 EDT

1.14

+0.01

+0.88%

最高1.16	最低1.14	成交量7.28万
今开1.15	昨收1.13	日振幅2.16%
总市值6,469万	流通市值5,020万	总股本5,675万
成交额8.37万	换手率0.17%	流通股本4,403万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TCRX","market":"US","secType":"STK","nameCN":"Tscan Therapeutics, Inc.","latestPrice":1.14,"timestamp":1773410321970,"preClose":1.13,"halted":0,"volume":72825,"delay":0,"changeRate":0.008849557522123902,"floatShares":44031318,"shares":56747993,"eps":-1,"marketStatus":"交易中","change":0.01,"latestTime":"03-13 09:58:48 EDT","open":1.15,"high":1.1594,"low":1.135,"amount":83676.09978,"amplitude":0.021593,"askPrice":1.14,"askSize":570,"bidPrice":1.13,"bidSize":910,"shortable":3,"etf":0,"ttmEps":-1,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1773432000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1626408000000,"exchange":"NASDAQ","adjPreClose":1.13,"preHourTrading":{"tag":"盘前","latestPrice":1.13,"preClose":1.13,"latestTime":"09:11 EDT","volume":4675,"amount":5425.79565,"timestamp":1773407511117,"change":0,"changeRate":0,"amplitude":0.115044},"postHourTrading":{"tag":"盘后","latestPrice":1.13,"preClose":1.13,"latestTime":"17:54 EDT","volume":413,"amount":471.72,"timestamp":1773352459733,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.271094},"requestUrl":"/m/hq/s/TCRX","defaultTab":"news","newsList":[{"id":"1150199578","title":"Tscan Therapeutics公司现金储备充足 预计可维持运营至2027年下半年","url":"https://stock-news.laohu8.com/highlight/detail?id=1150199578","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150199578?lang=zh_cn&edition=full","pubTime":"2026-03-04 20:13","pubTimestamp":1772626435,"startTime":"0","endTime":"0","summary":"生物技术企业Tscan Therapeutics, Inc.最新财务数据显示，其现有现金及现金等价物规模足以支撑公司日常运营与研发投入持续至2027年下半年。这一资金储备为该公司推进肿瘤靶向疗法研发提供了稳定的财务保障，显示出企业在资本管理方面的稳健态势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","TCRX","BK4139"],"gpt_icon":0},{"id":"1196850930","title":"Tscan Therapeutics计划于2026年下半年启动TSC-102双候选药物I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1196850930","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196850930?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:02","pubTimestamp":1772107377,"startTime":"0","endTime":"0","summary":"生物技术公司Tscan Therapeutics近日宣布，其研发管线中的重要候选药物TSC-102已确定临床开发时间表。根据最新规划，公司预计在2026年下半年正式启动针对TSC-102两项适应症的I期临床试验。\n这一进展标志着Tscan Therapeutics在肿瘤免疫治疗领域迈出关键一步。TSC-102作为公司核心研发项目，其临床试验的推进将为企业未来发展注入新动力。业界普遍关注该药物在实体瘤治疗方面的潜在突破，预计相关研究数据将为后续开发提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TCRX","BK4539","BK4139"],"gpt_icon":0},{"id":"1146298895","title":"TScan Therapeutics预计在截至12月31日的三个月内一次性支付230万美元的裁员费用","url":"https://stock-news.laohu8.com/highlight/detail?id=1146298895","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146298895?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:29","pubTimestamp":1763569752,"startTime":"0","endTime":"0","summary":"11月3日 - TScan Therapeutics Inc ::*TSCAN THERAPEUTICS INC - 预计在截至12月31日的三个月内一次性支付230万美元的裁员费用 - SEC文件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","TCRX"],"gpt_icon":0},{"id":"2584186666","title":"Tscan Therapeutics, Inc.2025财年第三财季实现净利润-35.71百万美元，同比减少19.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584186666","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584186666?lang=zh_cn&edition=full","pubTime":"2025-11-17 00:02","pubTimestamp":1763308978,"startTime":"0","endTime":"0","summary":"11月17日，Tscan Therapeutics, Inc.公布财报，公告显示公司2025财年第三财季净利润为-35.71百万美元，同比减少19.47%；其中营业收入为2.51百万美元，同比增加139.05%，每股基本收益为-0.28美元。从资产负债表来看，Tscan Therapeutics, Inc.总负债1.18亿美元，其中短期债务6.90百万美元，资产负债比为2.23，流动比率为0.07。机构评级：截至2025年11月17日，当前有5家机构对Tscan Therapeutics, Inc.目标价做出预测，其中目标均价为6.60美元，其中最低目标价为4.00美元，最高目标价为10.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117000319950817ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117000319950817ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TCRX"],"gpt_icon":0},{"id":"1182618270","title":"TScan Therapeutics Inc - 预计2025年12月31日止三个月内将产生230万美元的一次性裁员费用 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1182618270","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182618270?lang=zh_cn&edition=full","pubTime":"2025-11-03 19:38","pubTimestamp":1762169889,"startTime":"0","endTime":"0","summary":"TScan Therapeutics Inc - 预计2025年12月31日止三个月内将产生230万美元的一次性裁员费用 - SEC文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","TCRX"],"gpt_icon":0},{"id":"1181930115","title":"TScan暂停多重TCR-T疗法患者的进一步入组以优先发展血液学项目；重申计划在2026年第一季度公布数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1181930115","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181930115?lang=zh_cn&edition=full","pubTime":"2025-11-03 19:33","pubTimestamp":1762169589,"startTime":"0","endTime":"0","summary":"TScan宣布暂停对多重TCR-T疗法患者的进一步入组，旨在优先推进血液学领域的发展。同时，公司重申将在2026年第一季度公布相关数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","TCRX","BK4139"],"gpt_icon":0},{"id":"1105851613","title":"Tscan Therapeutics, Inc.宣布将在2025年美国风湿病学会大会上进行口头报告和海报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1105851613","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105851613?lang=zh_cn&edition=full","pubTime":"2025-09-17 19:01","pubTimestamp":1758106903,"startTime":"0","endTime":"0","summary":"Tscan Therapeutics, Inc.宣布将在2025年美国风湿病学会大会上进行口头报告和海报展示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","TCRX","BK4139"],"gpt_icon":0},{"id":"2518220126","title":"Tscan Therapeutics, Inc.盘中异动 股价大跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518220126","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518220126?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:49","pubTimestamp":1741628968,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日01时49分，Tscan Therapeutics, Inc.股票出现波动，股价急速下跌5.30%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.82%。其相关个股中，Aeon Biopharma, Inc.、Mineralys Therapeutics, Inc.、Checkpoint Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.较为活跃，换手率分别为5466.60%、3825.64%、991.14%，振幅较大的相关个股有Aeon Biopharma, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Biodexa Pharmaceuticals Plc，振幅分别为90.44%、88.14%、58.34%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311014928abf35ac8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311014928abf35ac8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","TCRX","BK4539"],"gpt_icon":0},{"id":"2518748289","title":"Tscan Therapeutics, Inc.2024财年实现净利润-1.27亿美元，同比减少42.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518748289","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518748289?lang=zh_cn&edition=full","pubTime":"2025-03-10 00:00","pubTimestamp":1741536046,"startTime":"0","endTime":"0","summary":"3月10日，Tscan Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.27亿美元，同比减少42.34%；其中营业收入为2.82百万美元，同比减少86.60%，每股基本收益为-1.14美元。从资产负债表来看，Tscan Therapeutics, Inc.总负债1.30亿美元，其中短期债务4.57百万美元，资产负债比为2.86，流动比率为0.09。机构评级：截至2025年3月10日，当前有7家机构对Tscan Therapeutics, Inc.目标价做出预测，其中目标均价为10.29美元，其中最低目标价为3.00美元，最高目标价为15.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000113a268980a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000113a268980a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TCRX","LENZ"],"gpt_icon":0},{"id":"2517443609","title":"Tscan Therapeutics, Inc.盘中异动 股价大跌5.45%报1.91美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517443609","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517443609?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:43","pubTimestamp":1741193030,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日00时43分，Tscan Therapeutics, Inc.股票出现异动，股价快速下挫5.45%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.04%。其相关个股中，Chimerix, Inc.、Nutriband Inc C/Wts 、Celularity Inc.涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为912.60%、299.54%、282.78%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 ，振幅分别为82.59%、54.27%、41.26%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306004351abe9d8d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306004351abe9d8d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4539","TCRX","BK4139"],"gpt_icon":0},{"id":"2517310944","title":"Needham：维持TScan Therapeutics(TCRX.US)评级，由买入调整至买入评级, 目标价由11.00美元调整至9.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517310944","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517310944?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:41","pubTimestamp":1741192881,"startTime":"0","endTime":"0","summary":"Needham：维持TScan Therapeutics(TCRX.US)评级，由买入调整至买入评级, 目标价由11.00美元调整至9.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06004148550592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","TCRX"],"gpt_icon":0},{"id":"1158846313","title":"TScan Therapeutics 2024年第四季度每股收益$(0.30)未达预期$(0.27)，销售额$66.5万未达预期$135万","url":"https://stock-news.laohu8.com/highlight/detail?id=1158846313","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158846313?lang=zh_cn&edition=full","pubTime":"2025-03-05 20:15","pubTimestamp":1741176918,"startTime":"0","endTime":"0","summary":"TScan Therapeutics报告第四季度每股亏损$，未达到分析师一致预期的$，差异为11.11%。与去年同期每股亏损$相比，这是一个42.86%的下降。以上内容来自Benzinga Earnings专栏，原文如下：TScan $Therapeutics$  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 11.11 percent. This is a 42.86 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $665.00 thousand which missed the analyst consensus estimate of $1.35 million by 50.74 percent.  This is a 90.78 percent decre","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TCRX","LENZ"],"gpt_icon":0},{"id":"2516658010","title":"Tscan Therapeutics, Inc.盘中异动 快速下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516658010","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516658010?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:41","pubTimestamp":1741016466,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时41分，Tscan Therapeutics, Inc.股票出现异动，股价快速下挫5.00%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.33%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Entero Therapeutics Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为2303.18%、137.90%、130.65%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为177.97%、70.53%、50.09%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303234107a25d5714&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303234107a25d5714&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TCRX","LENZ","BK4539","BK4139"],"gpt_icon":0},{"id":"2514382050","title":"Tscan Therapeutics, Inc.盘中异动 急速拉升5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514382050","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514382050?lang=zh_cn&edition=full","pubTime":"2025-02-28 00:24","pubTimestamp":1740673455,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日00时24分，Tscan Therapeutics, Inc.股票出现异动，股价大幅拉升5.76%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.60%。其相关个股中，Alpha Tau Medical Ltd C/Wts 、Heron Therapeutics, Inc.、Pepgen Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1654.91%、266.46%、112.45%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Quoin Pharmaceuticals Ltd、Pds Biotechnology Corporation，振幅分别为86.14%、47.79%、45.45%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502280024159632c887&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502280024159632c887&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4539","TCRX","BK4139"],"gpt_icon":0},{"id":"2514586274","title":"Tscan Therapeutics, Inc.盘中异动 急速跳水5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514586274","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514586274?lang=zh_cn&edition=full","pubTime":"2025-02-27 04:27","pubTimestamp":1740601670,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日04时27分，Tscan Therapeutics, Inc.股票出现异动，股价快速跳水5.12%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.65%。其相关个股中，Enveric Biosciences, Inc.、Renovaro Inc.、Salarius Pharmaceuticals, Inc.涨幅较大，Enveric Biosciences, Inc.、Aeon Biopharma, Inc.、Organovo Holdings, Inc.较为活跃，换手率分别为6843.34%、332.19%、264.99%，振幅较大的相关个股有Enveric Biosciences, Inc.、Renovaro Inc.、Immatics N V C/Wts 01/07/2025 ，振幅分别为194.07%、81.11%、70.39%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227042751abde3a5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227042751abde3a5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","LENZ","TCRX"],"gpt_icon":0},{"id":"2514077581","title":"Tscan Therapeutics, Inc.盘中异动 大幅下跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514077581","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514077581?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:54","pubTimestamp":1740412493,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时54分，Tscan Therapeutics, Inc.股票出现异动，股价急速下挫5.07%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为233.74%、100.01%、28.36%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ，振幅分别为151.09%、55.69%、53.34%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224235454962eac23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224235454962eac23&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TCRX","BK4539","LENZ"],"gpt_icon":0},{"id":"2513101218","title":"Tscan Therapeutics, Inc.盘中异动 急速拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513101218","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513101218?lang=zh_cn&edition=full","pubTime":"2025-02-22 01:19","pubTimestamp":1740158358,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日01时19分，Tscan Therapeutics, Inc.股票出现异动，股价急速拉升5.02%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.45%。其相关个股中，Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Osr Holdings, Inc.、Invivyd, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为239.47%、222.36%、128.50%，振幅较大的相关个股有Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Nkgen Biotech, Inc.，振幅分别为72.46%、57.50%、48.35%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222011919a24ed4eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222011919a24ed4eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TCRX","BK4539","BK4139"],"gpt_icon":0},{"id":"2512482724","title":"Tscan Therapeutics, Inc.盘中异动 临近午盘急速拉升5.44%报2.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512482724","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512482724?lang=zh_cn&edition=full","pubTime":"2025-02-20 00:32","pubTimestamp":1739982748,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日00时32分，Tscan Therapeutics, Inc.股票出现异动，股价急速拉升5.44%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.47%。其相关个股中，Osr Holdings, Inc.、Osr Holdings Inc C/Wts 02/09/2028 、Neurosense Therapeutics Ltd C/Wts 10/11/2026 涨幅较大，Aditxt, Inc.、Alzamend Neuro, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为587.85%、244.73%、197.64%，振幅较大的相关个股有Osr Holdings Inc C/Wts 02/09/2028 、Osr Holdings, Inc.、Aditxt, Inc.，振幅分别为207.68%、159.49%、48.18%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220003228988b44bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220003228988b44bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","LENZ","BK4139","TCRX"],"gpt_icon":0},{"id":"2512160456","title":"Tscan Therapeutics, Inc.盘中异动 股价大涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512160456","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512160456?lang=zh_cn&edition=full","pubTime":"2025-02-19 00:38","pubTimestamp":1739896697,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日00时38分，Tscan Therapeutics, Inc.股票出现异动，股价大幅上涨5.12%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.58%。其相关个股中，Estrella Immunopharma Inc C/Wts 29/09/2028、Solid Biosciences Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为395.73%、179.58%、150.74%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.，振幅分别为148.75%、92.00%、79.17%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219003817abd3ca90&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219003817abd3ca90&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4539","TCRX","BK4139"],"gpt_icon":0},{"id":"2511924536","title":"Tscan Therapeutics, Inc.盘中异动 早盘股价大涨5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511924536","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511924536?lang=zh_cn&edition=full","pubTime":"2025-02-14 23:56","pubTimestamp":1739548609,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日23时56分，Tscan Therapeutics, Inc.股票出现异动，股价大幅上涨5.39%。Tscan Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.73%。其相关个股中，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Allogene Therapeutics, Inc.涨幅较大，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为2607.67%、681.16%、512.63%，振幅较大的相关个股有Moleculin Biotech, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Klotho Neurosciences Inc C/Wts 21/06/2029 ，振幅分别为66.93%、54.40%、43.67%。Tscan Therapeutics, Inc.公司简介：TScan Therapeutics Inc 是一家生物制药公司，专注于开发用于治疗癌症患者的 T 细胞受体  工程化 T 细胞疗法 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214235649a2461420&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214235649a2461420&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TCRX","BK4539","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tscan.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.134},{"period":"3month","weight":0.1188},{"period":"6month","weight":-0.358},{"period":"1year","weight":-0.3722},{"period":"ytd","weight":0.13}],"compareEarnings":[{"period":"1week","weight":-0.0224},{"period":"1month","weight":-0.0377},{"period":"3month","weight":-0.023},{"period":"6month","weight":0.0132},{"period":"1year","weight":0.1918},{"period":"ytd","weight":-0.0233}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"TScan Therapeutics, Inc.于2018年4月17日在特拉华州注册成立。该公司是一家临床前阶段的生物制药公司，专注于开发强大的T细胞受体工程T细胞或TCR-T疗法，用于治疗癌症患者。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.002115},{"month":2,"riseRate":0.6,"avgChangeRate":0.133544},{"month":3,"riseRate":0.4,"avgChangeRate":-0.144398},{"month":4,"riseRate":0.5,"avgChangeRate":-0.003964},{"month":5,"riseRate":0.75,"avgChangeRate":0.125017},{"month":6,"riseRate":0.5,"avgChangeRate":-0.058009},{"month":7,"riseRate":0.75,"avgChangeRate":0.178095},{"month":8,"riseRate":0.4,"avgChangeRate":-0.114317},{"month":9,"riseRate":0.6,"avgChangeRate":0.003702},{"month":10,"riseRate":0.6,"avgChangeRate":0.083419},{"month":11,"riseRate":0.4,"avgChangeRate":-0.001328},{"month":12,"riseRate":0,"avgChangeRate":-0.252784}],"exchange":"NASDAQ","name":"Tscan Therapeutics, Inc.","nameEN":"Tscan Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tscan Therapeutics, Inc.(TCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Tscan Therapeutics, Inc.(TCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Tscan Therapeutics, Inc.,TCRX,Tscan Therapeutics, Inc.股票,Tscan Therapeutics, Inc.股票老虎,Tscan Therapeutics, Inc.股票老虎国际,Tscan Therapeutics, Inc.行情,Tscan Therapeutics, Inc.股票行情,Tscan Therapeutics, Inc.股价,Tscan Therapeutics, Inc.股市,Tscan Therapeutics, Inc.股票价格,Tscan Therapeutics, Inc.股票交易,Tscan Therapeutics, Inc.股票购买,Tscan Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tscan Therapeutics, Inc.(TCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Tscan Therapeutics, Inc.(TCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}